Cell-cycle arrest and senescence in TP53-wild type renal carcinoma by enhancer RNA-P53-bound enhancer regions 2 (p53BER2) in a p53-dependent pathway
Open accessAbstract
TP53 is a classic tumor suppressor, but its role in kidney cancer remains unclear. In our study, we tried to explain the role of p53 in kidney cancer through the p53-related enhancer RNA pathway. Functional experiments were used to explore whether P53-bound enhancer regions 2 (p53BER2) has a role in the cell cycle and senescence response of TP53-wild type (WT) renal cancer cells in vitro or vivo. RNA-sequencing was used to identify the potential target of p53BER2. The results showed that the expression level of P53BER2 was downregulated in renal cancer tissues and cell lines, further dual-luciferase experiments and APR-256-reactivated experiments showed p53BER2 expresses in a p53-dependent way. Moreover, knockdown p53BER2 could reverse nutlin-3-induced cytotoxic effect in TP53-WT cell lines. Further exploration showed the downregulation of p53BER2 could reverse nutlin-3-induced G1-arrest and senescence in TP53-WT cell lines. What is more, the knockdown of p53BER2 showed resistance to nutlin-3 treatment in vivo. Additionally, we found BRCA2 could be regulated by p53BER2 in vitro and vivo; further experiment showed p53BER2 could induce cell-cycle arrest and DNA repair by mediating BRCA2. In summary, the p53-associated enhancer RNA-p53BER2 mediates the cell cycle and senescence of p53 in TP53-WT renal cancer cells.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Methotrexate is a chemotherapeutic agent that inhibits DNA synthesis by targeting dihydrofolate reductase.
“Methotrexate (MTX) is a chemotherapeutic agent that inhibits DNA synthesis by targeting dihydrofolate reductase47, an enzyme needed for biosynthesis of nucleic acid precursors and some amino acids.”
From A statistical framework for high-content phenotypic profiling using cellular feature distributions (2022) · cites this paper as [47]
The Results discuss p53BER2, BRCA2, and DNA repair, while the Materials and methods name nutlin-3 and PRIMA-1-met as drugs used in the experiments. Searches for methotrexate, MTX, and dihydrofolate reductase found no passage addressing the claimed mechanism. Our copy therefore cannot verify this attribution. (LLM, conf=0.77)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 50 · Cited by 155
- Authors
- Xie, H., Ma, K., Zhang, K., Zhou, J., Li, L., Yang, W., Gong, Y., Cai, L., & Gong, K.
- Affiliations
- Peking University (CN)
- Corresponding author
- Gong, Yanqing
- Cai, Lin
- Gong, Kan
- Venue
- Cell Death & Disease
- Published
- 2021-01-05
- Volume
- 12
- Issue
- 1
- Pages
- 1-1
- ISSN
- 2041-4889 (ISSN-L)
- PMC
- PMC7791070
- OpenAlex
- W3111404439
- Cited by
- 155
- References
- 50
- Citations by year
- 2026: 5 · 2025: 38 · 2024: 32 · 2023: 30 · 2022: 32 · 2021: 18
- FWCI
- 10.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cell Death and Disease (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- National Natural Science Foundation of China (81872081)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Physiology › Telomeres, Telomerase, and Senescence
- Keywords
- p53, renal carcinoma, enhancer RNA, cell cycle arrest, cellular senescence, G1 cell cycle arrest, BRCA2, DNA repair, p53-dependent pathway
- MeSH terms
- Animals, Carcinoma, Renal Cell, Humans, Kidney Neoplasms, Male, Mice, Nude, Middle Aged, Transfection, Biomarkers, Tumor, Tumor Suppressor Protein p53, Cell Proliferation, Mice, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review